Compare Eli Lilly And Co (LLY) vs PAGSEG Inc (PAGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs PAGSEG Inc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while PAGSEG Inc trades at $11.16 (market cap $2.94B). The key difference: Eli Lilly And Co is far larger — about 353.7× PAGSEG Inc's market cap, and PAGSEG Inc pays the higher dividend (10.49%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and PAGSEG Inc for 26 Days on average.
| LLY | PAGS | |
|---|---|---|
Market Cap | $1.04T | $2.94B |
Volume | 3,064,878 | 4,242,708 |
Sector | Health | Industrials |
52-Week High | $1.28K | $12.00 |
52-Week Low | $799.57 | $8.44 |
Typical Hold Time | 93 Days | 26 Days |
Enterprise Value | $1.09T | $11.02B |
Dividend Yield | 0.59% | 10.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
PAGS trades at $10.68, up 1.62% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $10.70. The stock shows strong fundamentals with a P/E of 7.1, net income margin of 10.45%, and a dividend yield supported by a recent $0.28 payout. Recent earnings beat expectations in Q2 2026, and cash flow from operations remains robust at $7.56 billion for 2025.
The outlook is positive given undervaluation metrics and institutional support, but risks include a projected negative net cash flow for 2026 and high RSI levels suggesting overbought conditions. Earnings growth and banking segment expansion are key catalysts, while macroeconomic pressures in Brazil present headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
